Sanofi

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharmaceuticals Inc.

Rosy Sher

Raymond W Kosley, Jr

Stephen J Shimshock

Holger Heitsch

Stephanie Hachtel

Aleksandra Weichsel

Juergen Dedio

Sven Grueneberg

Werngard Czechtizky

Carolina Lanter

Hui Li

Elisabeth Defossa

John G Jurcak

Patrick Jimonet

Marcel Patek

Matthieu Barrague

Joseph Guiles

Ryan E Hartung

Sathapana Kongsamut

Bin Cao

Douglas Macdonald

William Jerome Bock

Raymond Kosley

Xu-Yang Zhao

Paul Justin Mueller

Chung-Yi Kung

Jennifer Beall

Charlie Chen

Vieroslava Gurunian

William Bock

Jr Raymond W Kosley

Stephen Shimshock

Raymond Walter Kosley

Paul J Mueller

Joseph W Guiles

Hui Sanofi-Aventis Us Inc Li

Stephen Sanofi-Aventis Us Inc Shimshock

The present invention relates to a series of substituted dihydro benzocycloalkyl-oxymethyl oxazolopyrimidinones of formula (I): Wherein n, R, R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, cognition deficit disorders, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof

The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R, R, R, R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof

The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

CXCR2 inhibitors

The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

The present disclosure relates to a series of 2-substituted-di- tri or tetra-hydro-8H-cyclopentaoxazolo[3,2-a]pyrimidin-8-ones and 2-substituted-di-, tetra-, or hexa-hydro-cyclohexaoxazolo[3,2-a]pyrimidin-9-ones of formula (I): wherein p, n, A, B, X, Y, R, R, R, R, R, R, Rand Rare as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof

The present invention is directed to dipyrazole compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I.  The compounds of this invention modulate AMPA and NMDA receptor function, and therefore are useful as pharmaceutical agents, especially for the treatment of neuropsychiatric disorders.

Dipyrazole compounds and their use as central nervous system agents

A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R, R, Rand X are as defined herein.

N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof

Growing community of inventors

Bridgewater, NJ, United States of America

Rosy Sher